...issued feedback on proposed modifications to address COVID-related impacts to a Phase III study in osteoarthritis...

...Claire Quang, Staff Writer DISEASE CATEGORY: MusculoskeletalINDICATION: OsteoarthritisInhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis...
...reduced expression of COL2A1 and cartilage-degrading enzymes ADAMTS4 and ADAMTS5. In a mouse model of osteoarthritis...
...Dell’Accio, same affiliation as aboveemail: fdellaccio@gmail.com Claire Quang Queen Mary University of London Receptor tyrosine kinase-like orphan receptor 2 (ROR2) Autoimmune Osteoarthritis...

...raised nearly $1.7 billion towards its year-end goal of $2 billion for COVAX AMC.Novartis gains Phase II-ready osteoarthritis...
...Merck KGaANovartis AG (NYSE:NVS; SIX:NOVN) in-licensed development and commercialization rights to M6495, a Phase II-ready osteoarthritis...

...part because the long-acting steroid injection for osteoarthritis...

...and DYRK1A, in Phase III testing for osteoarthritis...

...cap By Virginia Li, Associate Editor  After the failure of its lead anti-aging program in osteoarthritis...
...WOMAC-A vs. placebo in a Phase II study of patients with moderate to severe painful osteoarthritis...
...the eye. We’re arranging resources to go after many things at once.”In the case of osteoarthritis...

...this week. Regeneron’s osteoarthritis mAb meets in two pivotal trials Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said osteoarthritis...

...AstraZeneca plc (LSE:AZN; NYSE:AZN) has the PAR2 antagonist mAb MEDI0618 in Phase I testing for osteoarthritis...

...report an unexpected boost in sales during the COVID-19 pandemic with second quarter sales for osteoarthritis...

...FGF18. Merck KGaA (Xetra:MRK) has completed Phase II testing of recombinant FGF18 sprifermin (AS902330) for osteoarthritis...